Cost and efficacy examination of alvimopan for the prevention of postoperative ileus

Zoltan H. Nemeth, Dorian A. Bogdanovski, Samantha R. Paglinco, Patricia Barratt-Stopper, Rolando H. Rolandelli

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Opioid analgesics exacerbate ileus through peripheral μ-opioid receptor action. Alvimopan, a μ-opioid receptor antagonist, has been proposed to alleviate postoperative ileus, leading to decreased time to return of gastrointestinal function and hospital discharge. As opioid-induced motility issues are only one factor affecting postoperative ileus, continued examination of the cost of the use and efficacy of the drug is needed. Data for this study were collected retrospectively from the charts of 55 patients who received an anastomosis and were given alvimopan at Morristown Medical Center between 2010 and 2013 as well as from 58 appropriately matched controls. The billing record and chart for each patient was examined, and information on total hospital charges, age, sex, body mas index, primary diagnosis, procedure type, length of stay (days), time to return of bowel function (hours), and outcomes were recorded for analysis. No difference between patients given alvimopan and controls was observed for the length of hospital stay (4.6 vs 4.8 days) or for time to return of bowel function (68.5 vs 67.3 hours). Total hospital charges were higher for treated patients (p=0.0080), averaging $48 705.15 and $41 068.80, respectively. Alvimopan was not associated with improved clinical outcome but was associated with an increase in hospital charges within this population.

Original languageEnglish (US)
Pages (from-to)949-952
Number of pages4
JournalJournal of Investigative Medicine
Volume65
Issue number5
DOIs
StatePublished - Jun 1 2017
Externally publishedYes

Fingerprint

alvimopan
Ileus
Hospital Charges
Costs and Cost Analysis
Length of Stay
Opioid Analgesics
Costs
Narcotic Antagonists
Opioid Receptors
Pharmaceutical Preparations
Population

All Science Journal Classification (ASJC) codes

  • Biochemistry, Genetics and Molecular Biology(all)

Cite this

Nemeth, Zoltan H. ; Bogdanovski, Dorian A. ; Paglinco, Samantha R. ; Barratt-Stopper, Patricia ; Rolandelli, Rolando H. / Cost and efficacy examination of alvimopan for the prevention of postoperative ileus. In: Journal of Investigative Medicine. 2017 ; Vol. 65, No. 5. pp. 949-952.
@article{5e7ee1cbb5f34e4b851cd06f64ea42e6,
title = "Cost and efficacy examination of alvimopan for the prevention of postoperative ileus",
abstract = "Opioid analgesics exacerbate ileus through peripheral μ-opioid receptor action. Alvimopan, a μ-opioid receptor antagonist, has been proposed to alleviate postoperative ileus, leading to decreased time to return of gastrointestinal function and hospital discharge. As opioid-induced motility issues are only one factor affecting postoperative ileus, continued examination of the cost of the use and efficacy of the drug is needed. Data for this study were collected retrospectively from the charts of 55 patients who received an anastomosis and were given alvimopan at Morristown Medical Center between 2010 and 2013 as well as from 58 appropriately matched controls. The billing record and chart for each patient was examined, and information on total hospital charges, age, sex, body mas index, primary diagnosis, procedure type, length of stay (days), time to return of bowel function (hours), and outcomes were recorded for analysis. No difference between patients given alvimopan and controls was observed for the length of hospital stay (4.6 vs 4.8 days) or for time to return of bowel function (68.5 vs 67.3 hours). Total hospital charges were higher for treated patients (p=0.0080), averaging $48 705.15 and $41 068.80, respectively. Alvimopan was not associated with improved clinical outcome but was associated with an increase in hospital charges within this population.",
author = "Nemeth, {Zoltan H.} and Bogdanovski, {Dorian A.} and Paglinco, {Samantha R.} and Patricia Barratt-Stopper and Rolandelli, {Rolando H.}",
year = "2017",
month = "6",
day = "1",
doi = "10.1136/jim-2017-000449",
language = "English (US)",
volume = "65",
pages = "949--952",
journal = "Journal of Investigative Medicine",
issn = "1081-5589",
publisher = "Lippincott Williams and Wilkins",
number = "5",

}

Cost and efficacy examination of alvimopan for the prevention of postoperative ileus. / Nemeth, Zoltan H.; Bogdanovski, Dorian A.; Paglinco, Samantha R.; Barratt-Stopper, Patricia; Rolandelli, Rolando H.

In: Journal of Investigative Medicine, Vol. 65, No. 5, 01.06.2017, p. 949-952.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Cost and efficacy examination of alvimopan for the prevention of postoperative ileus

AU - Nemeth, Zoltan H.

AU - Bogdanovski, Dorian A.

AU - Paglinco, Samantha R.

AU - Barratt-Stopper, Patricia

AU - Rolandelli, Rolando H.

PY - 2017/6/1

Y1 - 2017/6/1

N2 - Opioid analgesics exacerbate ileus through peripheral μ-opioid receptor action. Alvimopan, a μ-opioid receptor antagonist, has been proposed to alleviate postoperative ileus, leading to decreased time to return of gastrointestinal function and hospital discharge. As opioid-induced motility issues are only one factor affecting postoperative ileus, continued examination of the cost of the use and efficacy of the drug is needed. Data for this study were collected retrospectively from the charts of 55 patients who received an anastomosis and were given alvimopan at Morristown Medical Center between 2010 and 2013 as well as from 58 appropriately matched controls. The billing record and chart for each patient was examined, and information on total hospital charges, age, sex, body mas index, primary diagnosis, procedure type, length of stay (days), time to return of bowel function (hours), and outcomes were recorded for analysis. No difference between patients given alvimopan and controls was observed for the length of hospital stay (4.6 vs 4.8 days) or for time to return of bowel function (68.5 vs 67.3 hours). Total hospital charges were higher for treated patients (p=0.0080), averaging $48 705.15 and $41 068.80, respectively. Alvimopan was not associated with improved clinical outcome but was associated with an increase in hospital charges within this population.

AB - Opioid analgesics exacerbate ileus through peripheral μ-opioid receptor action. Alvimopan, a μ-opioid receptor antagonist, has been proposed to alleviate postoperative ileus, leading to decreased time to return of gastrointestinal function and hospital discharge. As opioid-induced motility issues are only one factor affecting postoperative ileus, continued examination of the cost of the use and efficacy of the drug is needed. Data for this study were collected retrospectively from the charts of 55 patients who received an anastomosis and were given alvimopan at Morristown Medical Center between 2010 and 2013 as well as from 58 appropriately matched controls. The billing record and chart for each patient was examined, and information on total hospital charges, age, sex, body mas index, primary diagnosis, procedure type, length of stay (days), time to return of bowel function (hours), and outcomes were recorded for analysis. No difference between patients given alvimopan and controls was observed for the length of hospital stay (4.6 vs 4.8 days) or for time to return of bowel function (68.5 vs 67.3 hours). Total hospital charges were higher for treated patients (p=0.0080), averaging $48 705.15 and $41 068.80, respectively. Alvimopan was not associated with improved clinical outcome but was associated with an increase in hospital charges within this population.

UR - http://www.scopus.com/inward/record.url?scp=85020234966&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85020234966&partnerID=8YFLogxK

U2 - 10.1136/jim-2017-000449

DO - 10.1136/jim-2017-000449

M3 - Article

C2 - 28566386

AN - SCOPUS:85020234966

VL - 65

SP - 949

EP - 952

JO - Journal of Investigative Medicine

JF - Journal of Investigative Medicine

SN - 1081-5589

IS - 5

ER -